Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3+ regulatory T cells

Clinical and Experimental Immunology

Volumn 178, Issue 2, 2014, Pages 253-261

  Tanaka, H ^a,d   Zhang, W ^a   Yang, G X ^a   Ando, Y ^e   Tomiyama, T ^a,e   Tsuneyama, K ^f   Leung, P ^a   Coppel, R L ^g   Ansari, A A ^b   Lian, Z X ^h   Ridgway, W M ^c   Joh, T ^d   Gershwin, M E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e KANSAI MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g MONASH UNIVERSITY   (Australia)

^h UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Autoimmunity; Cholangitis; Colitis; Murine models; Primary biliary cirrhosis

Indexed keywords

CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; AUTOIMMUNE DISEASES; BIOSYNTHESIS; C57BL MOUSE; CHOLANGITIS; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; IMMUNOPHENOTYPING; MALE; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE;

ANIMALS; AUTOIMMUNE DISEASES; CHOLANGITIS; CYTOKINES; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; SPLEEN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84908202760     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12415     Document Type: Article

References (53)

1. Fort MM, Narayanan PK. Manipulation of regulatory T-cell function by immunomodulators: a boon or a curse? Toxicol Sci 2010; 117:253-262.
2. Sakaguchi S, Sakaguchi N, Shimizu J etal. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182:18-32.
3. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell 2008; 133:775-787.
4. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2:816-822.
5. Schneider-Hohendorf T, Stenner MP, Weidenfeller C etal. Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. Eur J Immunol 2010; 40:3581-3590.
6. Lin X, Chen M, Liu Y etal. Advances in distinguishing natural from induced FoxP3(+) regulatory T cells. Int J Clin Exp Pathol 2013; 6:116-123.
7. Beriou G, Costantino CM, Ashley CW etal. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009; 113:4240-4249.
8. Sakuraba K, Shibata K, Iwamoto Y, Yoshikai Y, Yamada H. Naturally occurring PD-1+ memory phenotype CD8 T cells belong to nonconventional CD8 T cells and are cyclophosphamide-sensitive regulatory T cells. J Immunol 2013; 190:1560-1566.
9. Oertelt S, Lian ZX, Cheng CM etal. Anti-mitochondrial antibodies and advances in distinguishing natural from induced FoxP3(+) regulatory T cellsprimary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol 2006; 177:1655-1660.
10. Yang GX, Lian ZX, Chuang YH etal. Adoptive transfer of CD8(+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice. Hepatology 2008; 47:1974-1982.
11. Kawata K, Yang GX, Ando Y etal. Clonality, activated antigen-specific CD8(+) T cells, and development of autoimmune cholangitis in dnTGFbetaRII mice. Hepatology 2013; 58:1094-1104.
12. Huang W, Kachapati K, Adams D etal. Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1 CD8 effector cells and defective T regulatory cells. J Autoimmun 2014; 50:123-134.
13. d'Hennezel E, Piccirillo CA. Analysis of human FOXP3+ Treg cells phenotype and function. Methods Mol Biol 2011; 707:199-218.
14. Tsuda M, Zhang W, Yang GX etal. Deletion of interleukin (IL)-12p35 induces liver fibrosis in dominant-negative TGFbeta receptor type II mice. Hepatology 2013; 57:806-816.
15. Ando Y, Yang GX, Tsuda M etal. The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice. Hepatology 2012; 56:1418-1426.
16. Yoshida K, Yang GX, Zhang W etal. Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice. Hepatology 2009; 50:1494-1500.
17. Ishigame H, Mosaheb MM, Sanjabi S, Flavell RA. Truncated form of TGF-betaRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice. J Immunol 2013; 190:6340-6350.
18. Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006; 25:455-471.
19. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2002; 2:46-53.
20. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008; 134:392-404.
21. Cobbold SP, Castejon R, Adams E etal. Induction of FoxP3+ regulatory T cells in the periphery of T cell receptor transgenic mice tolerized to transplants. J Immunol 2004; 172:6003-6010.
22. Chen W, Jin W, Hardegen N etal. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor FoxP3. J Exp Med 2003; 198:1875-1886.
23. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through FoxP3 induction and down-regulation of Smad7. J Immunol 2004; 172:5149-5153.
24. Ouyang W, Beckett O, Ma Q, Li MO. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 2010; 32:642-653.
25. Peng Y, Laouar Y, Li MO, Green EA, Flavell RA. TGF-beta regulates in vivo expansion of FoxP3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101:4572-4577.
26. Marie JC, Liggitt D, Rudensky AY. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006; 25:441-454.
27. Lan RY, Cheng C, Lian ZX etal. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43:729-737.
28. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci USA 2004; 101:10398-10403.
29. Sojka DK, Hughson A, Fowell DJ. CTLA-4 is required by CD4+CD25+ Treg to control CD4+ T-cell lymphopenia-induced proliferation. Eur J Immunol 2009; 39:1544-1551.
30. Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci USA 2009; 106:13445-13450.
31. Dhamne C, Chung Y, Alousi AM, Cooper LJ, Tran DQ. Peripheral and thymic FoxP3(+) regulatory T cells in search of origin, distinction, and function. Front Immunol 2013; 4:253.
32. Zhou AX, Kozhaya L, Fujii H, Unutmaz D. GARP-TGF-beta complexes negatively regulate regulatory T cell development and maintenance of peripheral CD4+ T cells in vivo. J Immunol 2013; 190:5057-5064.
33. Edwards JP, Fujii H, Zhou AX, Creemers J, Unutmaz D, Shevach EM. Regulation of the expression of GARP/latent TGF-beta1 complexes on mouse T cells and their role in regulatory T cell and Th17 differentiation. J Immunol 2013; 190:5506-5515.
34. Deaglio S, Dwyer KM, Gao W etal. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-1265.
35. Chang LY, Lin YC, Kang CW etal. The indispensable role of CCR5 for in vivo suppressor function of tumor-derived CD103+ effector/memory regulatory T cells. J Immunol 2012; 189:567-574.
36. Regateiro FS, Howie D, Nolan KF etal. Generation of anti-inflammatory adenosine by leukocytes is regulated by TGF-beta. Eur J Immunol 2011; 41:2955-2965.
37. Takimoto T, Wakabayashi Y, Sekiya T etal. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J Immunol 2010; 185:842-855.
38. Reynolds LA, Maizels RM. Cutting edge: in the absence of TGF-beta signaling in T cells, fewer CD103+ regulatory T cells develop, but exuberant IFN-gamma production renders mice more susceptible to helminth infection. J Immunol 2012; 189:1113-1117.
39. Robinson PW, Green SJ, Carter C, Coadwell J, Kilshaw PJ. Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology 2001; 103:146-154.
40. Suffia I, Reckling SK, Salay G, Belkaid Y. A role for CD103 in the retention of CD4+CD25+ Treg and control of Leishmania major infection. J Immunol 2005; 174:5444-5455.
41. Invernizzi P. Liver auto-immunology: the paradox of autoimmunity in a tolerogenic organ. J Autoimmun 2013; 46:1-6.
42. Trivedi PJ, Adams DH. Mucosal immunity in liver autoimmunity: a comprehensive review. J Autoimmun 2013; 46:97-111.
43. Hudspeth K, Pontarini E, Tentorio P etal. The role of natural killer cells in autoimmune liver disease: a comprehensive review. J Autoimmun 2013; 46:55-65.
44. Yang CY, Ma X, Tsuneyama K etal. IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology 2014; 59:1944-1953.
45. Tanaka H, Yang GX, Iwakoshi N etal. Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clin Exp Immunol 2013; 174:364-371.
46. Rong GH, Yang GX, Ando Y etal. Human intrahepatic biliary epithelial cells engulf blebs from their apoptotic peers. Clin Exp Immunol 2013; 172:95-103.
47. Leung PS, Wang J, Naiyanetr P etal. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. J Autoimmun 2013; 41:79-86.
48. Chen RC, Naiyanetr P, Shu SA etal. Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology 2013; 57:1498-1508.
49. Yao Y, Yang W, Yang YQ etal. Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha(-/-) mice. J Autoimmun 2014; 51:99-108.
50. Chang CH, Chen YC, Yu YH etal. Innate immunity drives xenobiotic-induced murine autoimmune cholangitis. Clin Exp Immunol 2014; 177:373-380.
51. Lleo A, Zhang W, McDonald WH etal. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology 2014. doi: 10.1002/hep.27230.
52. Jin Q, Moritoki Y, Lleo A etal. Comparative analysis of portal cell infiltrates in antimitochondrial autoantibody-positive versus antimitochondrial autoantibody-negative primary biliary cirrhosis. Hepatology 2012; 55:1495-1506.
53. Takahashi T, Miura T, Nakamura J etal. Plasma cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis. Hepatology 2012; 55:846-855.